-
1
-
-
0008460054
-
Physicochemical methods of detection of a previously unidentified adrenal hormone
-
Simpson SA, Tait JF. Physicochemical methods of detection of a previously unidentified adrenal hormone. Mem Soc Endocrinol 1953; 2: 9-24.
-
(1953)
Mem Soc Endocrinol
, vol.2
, pp. 9-24
-
-
Simpson, S.A.1
Tait, J.F.2
-
4
-
-
0038036757
-
Aldosterone receptor blockade: A therapy resurrected
-
Sica DA. Aldosterone receptor blockade: a therapy resurrected. Heart Dis 2003; 5: 85-8.
-
(2003)
Heart Dis
, vol.5
, pp. 85-88
-
-
Sica, D.A.1
-
6
-
-
0027997406
-
Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells
-
Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-20.
-
(1994)
J Biol Chem
, vol.269
, pp. 24316-24320
-
-
Hatakeyama, H.1
Miyamori, I.2
Fujita, T.3
Takeda, Y.4
Takeda, R.5
Yamamoto, H.6
-
7
-
-
0029788193
-
Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin
-
Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81: 2797-800.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, pp. 2797-2800
-
-
Takeda, Y.1
Miyamori, I.2
Yoneda, T.3
-
8
-
-
8544279579
-
Aldosterone biosynthesis in the rat brain
-
Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foucking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997; 138: 3369-73.
-
(1997)
Endocrinology
, vol.138
, pp. 3369-3373
-
-
Gomez-Sanchez, C.E.1
Zhou, M.Y.2
Cozza, E.N.3
Morita, H.4
Foucking, M.F.5
Gomez-Sanchez, E.P.6
-
9
-
-
0032570807
-
Myocardial production of aldosterone and corticosterone in the rat: Physiological regulation
-
Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 1998; 273: 4883-91.
-
(1998)
J Biol Chem
, vol.273
, pp. 4883-4891
-
-
Silvestre, J.S.1
Robert, V.2
Heymes, C.3
-
10
-
-
0035072588
-
Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats
-
Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001; 19: 635-9.
-
(2001)
J Hypertens
, vol.19
, pp. 635-639
-
-
Takeda, Y.1
Yoneda, T.2
Demura, M.3
Furukawa, K.4
Miyamori, I.5
Mabuchi, H.6
-
11
-
-
0024329644
-
Molecular cloning of a mineralocorticoid (type 1) receptor complementary DNA, from rat hippocampus
-
Patel PD, Sherman TJ, Goldman DJ, Watson SJ. Molecular cloning of a mineralocorticoid (type 1) receptor complementary DNA, from rat hippocampus. Mol Endocrinol 1989; 3: 1877-85.
-
(1989)
Mol Endocrinol
, vol.3
, pp. 1877-1885
-
-
Patel, P.D.1
Sherman, T.J.2
Goldman, D.J.3
Watson, S.J.4
-
12
-
-
0029022285
-
Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart
-
Lombes M, Alfaidy N, Eugene E, Lessana A, Barman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-82.
-
(1995)
Circulation
, vol.92
, pp. 175-182
-
-
Lombes, M.1
Alfaidy, N.2
Eugene, E.3
Lessana, A.4
Barman, N.5
Bonvalet, J.P.6
-
13
-
-
0024442132
-
Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors
-
Funder JW, Pearce PT, Smith R, Campbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989; 125: 2224-6.
-
(1989)
Endocrinology
, vol.125
, pp. 2224-2226
-
-
Funder, J.W.1
Pearce, P.T.2
Smith, R.3
Campbell, J.4
-
14
-
-
0031041163
-
Vascular aldosterone in genetically hypertensive rats
-
Takeda Y, Miyamori I, Inaba S, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29: 45-8.
-
(1997)
Hypertension
, vol.29
, pp. 45-48
-
-
Takeda, Y.1
Miyamori, I.2
Inaba, S.3
-
15
-
-
84954981008
-
The general adaptation syndrome and the diseases of adaptation
-
Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946; 6: 117-230.
-
(1946)
J Clin Endocrinol
, vol.6
, pp. 117-230
-
-
Selye, H.1
-
16
-
-
0025770664
-
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
-
Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
-
(1991)
Circulation
, vol.83
, pp. 1849-1865
-
-
Weber, K.T.1
Brilla, C.G.2
-
17
-
-
0025675680
-
Remodeling of the rat right and left ventricle in experimental hypertension
-
Brilla CG, Pick R, Tan LP, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 67: 1355-64.
-
(1990)
Circ Res
, vol.67
, pp. 1355-1364
-
-
Brilla, C.G.1
Pick, R.2
Tan, L.P.3
Janicki, J.S.4
Weber, K.T.5
-
18
-
-
0028785677
-
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
-
Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657-E662.
-
(1995)
Am J Physiol
, vol.269
-
-
Young, M.1
Head, G.2
Funder, J.3
-
19
-
-
0029805353
-
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis
-
Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996; 271: E883-E888.
-
(1996)
Am J Physiol
, vol.271
-
-
Young, M.J.1
Funder, J.W.2
-
20
-
-
0034031440
-
Cardiac aldosterone production and ventricular remodeling
-
Delcayre C, Silvestre JS, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-51.
-
(2000)
Kidney Int
, vol.57
, pp. 1346-1351
-
-
Delcayre, C.1
Silvestre, J.S.2
Garnier, A.3
-
21
-
-
0027499223
-
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
-
Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A.
-
(1993)
Am J Cardiol
, vol.71
-
-
Brilla, C.G.1
Matsubara, L.S.2
Weber, K.T.3
-
22
-
-
0035131479
-
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats
-
Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37: 662-7.
-
(2001)
J Am Coll Cardiol
, vol.37
, pp. 662-667
-
-
Lacolley, P.1
Safar, M.E.2
Lucet, B.3
Ledudal, K.4
Labat, C.5
Benetos, A.6
-
23
-
-
0029022658
-
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone
-
Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995; 26: 101-11.
-
(1995)
Hypertension
, vol.26
, pp. 101-111
-
-
Nicoletti, A.1
Heudes, D.2
Hinglais, N.3
-
24
-
-
0031600240
-
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
-
Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-8.
-
(1998)
Hypertension
, vol.31
, pp. 451-458
-
-
Rocha, R.1
Chander, P.N.2
Khanna, K.3
Zuckerman, A.4
Stier Jr., C.T.5
-
25
-
-
0033849916
-
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
-
Brown NJ, Nakamura S, Ma LJ, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-27.
-
(2000)
Kidney Int
, vol.58
, pp. 1219-1227
-
-
Brown, N.J.1
Nakamura, S.2
Ma, L.J.3
-
26
-
-
0028982073
-
Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β
-
Ikeda U, Kanbe T, Nakayama Y, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol 1995; 290: 69-73.
-
(1995)
Eur J Pharmacol
, vol.290
, pp. 69-73
-
-
Ikeda, U.1
Kanbe, T.2
Nakayama, Y.3
Kawahara, Y.4
Yokoyama, M.5
Shimada, K.6
-
27
-
-
0026688810
-
Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses
-
Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73.
-
(1992)
Hypertension
, vol.20
, pp. 67-73
-
-
Ullian, M.E.1
Schelling, J.R.2
Linas, S.L.3
-
28
-
-
0027436742
-
Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterore
-
Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterore. J Lab Clin Med 1993; 122: 395-403.
-
(1993)
J Lab Clin Med
, vol.122
, pp. 395-403
-
-
Sun, Y.1
Ratajska, A.2
Zhou, G.3
Weber, K.T.4
-
29
-
-
0030222294
-
Potentiation of angiotensin II action by corticosteroids in vascular tissue
-
Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32: 266-73.
-
(1996)
Cardiovasc Res
, vol.32
, pp. 266-273
-
-
Ullian, M.E.1
Walsh, L.G.2
Morinelli, T.A.3
-
31
-
-
0028275578
-
Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone
-
Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-20.
-
(1994)
J Mol Cell Cardiol
, vol.26
, pp. 809-820
-
-
Brilla, C.G.1
Zhou, G.2
Matsubara, L.3
Weber, K.T.4
-
32
-
-
85047676796
-
Aldosterone and cardiac fibrosis: In vitro studies
-
Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28: 1863-7.
-
(1994)
Cardiovasc Res
, vol.28
, pp. 1863-1867
-
-
Fullerton, M.J.1
Funder, J.W.2
-
33
-
-
0029931451
-
Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?
-
Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 1996; 33: 315-26.
-
(1996)
J Vasc Res
, vol.33
, pp. 315-326
-
-
Kohler, E.1
Bertschin, S.2
Woodtli, T.3
Resink, T.4
Erne, P.5
-
34
-
-
0036838616
-
Aldosterone induces a vascular inflammatory phenotype in the rat heart
-
Rocha R, Rudolph AE, Friedrich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: H1802-H1810.
-
(2002)
Am J Physiol
, vol.283
-
-
Rocha, R.1
Rudolph, A.E.2
Friedrich, G.E.3
-
35
-
-
0036841807
-
Aldosterone-induced inflammation in the rat heart. Role of oxidative stress
-
Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002; 161: 1773-81.
-
(2002)
Am J Pathol
, vol.161
, pp. 1773-1781
-
-
Sun, Y.1
Zhang, J.2
Lu, L.3
Chen, S.S.4
Quinn, M.T.5
Weber, K.T.6
-
36
-
-
0038299329
-
Aldosteronism: An immunostimulatory state precedes proinflammatory/ fibrogenic cardiac phenotype
-
Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol 2003; 285: H813-H821.
-
(2003)
Am J Physiol
, vol.285
-
-
Gerling, I.C.1
Sun, Y.2
Ahokas, R.A.3
-
37
-
-
0035985329
-
Aldosterone and PAI-1: Implications for renal injury
-
Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002; 15: 230-5.
-
(2002)
J Nephrol
, vol.15
, pp. 230-235
-
-
Brown, N.J.1
Vaughan, D.E.2
Fogo, A.B.3
-
38
-
-
0033745021
-
Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
-
Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.
-
(2000)
Endocrinology
, vol.141
, pp. 3871-3878
-
-
Rocha, R.1
Stier Jr., C.T.2
Kifor, I.3
-
39
-
-
0037813769
-
Effect of spironolactone on impaired fibrinolysis of hypertensive patients
-
Yalcin AU, Dincer M, Aslan V, Gulbas Z. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002; 25: 260-4.
-
(2002)
Kidney Blood Press Res
, vol.25
, pp. 260-264
-
-
Yalcin, A.U.1
Dincer, M.2
Aslan, V.3
Gulbas, Z.4
-
40
-
-
0036893647
-
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart
-
Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-36.
-
(2002)
Endocrinology
, vol.143
, pp. 4828-4836
-
-
Rocha, R.1
Martin-Berger, C.L.2
Yang, P.3
Scherrer, R.4
Delyani, J.5
McMahon, E.6
-
41
-
-
6444245944
-
Therapeutic benefit of spironolactone in experimental chronic cyclosporine a nephrotoxicity
-
Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.
-
(2003)
Kidney Int
, vol.63
, pp. 43-52
-
-
Feria, I.1
Pichardo, I.2
Juarez, P.3
-
42
-
-
0036791717
-
Spironolactone improves angiotensin-induced vascular changes and oxidative stress
-
Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-10.
-
(2002)
Hypertension
, vol.40
, pp. 504-510
-
-
Virdis, A.1
Neves, M.F.2
Amiri, F.3
Viel, E.4
Touyz, R.M.5
Schiffrin, E.L.6
-
43
-
-
0034457808
-
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
-
Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-44.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 336-344
-
-
Brown, N.J.1
Kim, K.S.2
Chen, Y.Q.3
-
44
-
-
0034518414
-
PAI-1, fibrosis and the elusive provisional fibrin matrix
-
Loskutoff DJ, Quigley JP. PAI-1, fibrosis and the elusive provisional fibrin matrix. J Clin Invest 2000; 106: 1441-3.
-
(2000)
J Clin Invest
, vol.106
, pp. 1441-1443
-
-
Loskutoff, D.J.1
Quigley, J.P.2
-
45
-
-
0030939082
-
Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma
-
Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-8.
-
(1997)
Circulation
, vol.95
, pp. 1471-1478
-
-
Rossi, G.P.1
Sacchetto, A.2
Pavan, E.3
-
46
-
-
0033128379
-
Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-sectional Primary Aldosteronism and Heart Italian Multicenter Study
-
Napoli C, DiGregorio F, Leccese M, et al. Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: the Cross-sectional Primary Aldosteronism and Heart Italian Multicenter Study. J Invest Med 1999; 47: 212-21.
-
(1999)
J Invest Med
, vol.47
, pp. 212-221
-
-
Napoli, C.1
DiGregorio, F.2
Leccese, M.3
-
47
-
-
0029558829
-
Albuminuria in untreated patients with primary aldosteronism or essential hypertension
-
Halimi JM, Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801-2.
-
(1995)
J Hypertens
, vol.13
, pp. 1801-1802
-
-
Halimi, J.M.1
Mimram, A.2
-
48
-
-
0029007648
-
Vascular complications in patients with aldosterone producing adenoma in Japan: Comparative study with essential hypertension
-
Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T, for the Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370-3.
-
(1995)
J Endocrinol Invest
, vol.18
, pp. 370-373
-
-
Takeda, R.1
Matsubara, T.2
Miyamori, I.3
Hatakeyama, H.4
Morise, T.5
-
49
-
-
0033044504
-
Cardiovascular complications in patients with primary aldosteronism
-
Nishimura M, Uzu T, Fuji T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-6.
-
(1999)
Am J Kidney Dis
, vol.33
, pp. 261-266
-
-
Nishimura, M.1
Uzu, T.2
Fuji, T.3
-
50
-
-
0035960677
-
Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease
-
Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzefl T. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
-
(2001)
Circulation
, vol.104
, pp. 2673-2678
-
-
Heitzer, T.1
Schlinzig, T.2
Krohn, K.3
Meinertz, T.4
Munzefl, T.5
-
51
-
-
0027245468
-
Vasodilation to acetylcholine in primary and secondary forms of human hypertension
-
Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.
-
(1993)
Hypertension
, vol.21
, pp. 929-933
-
-
Taddei, S.1
Virdis, A.2
Mattei, P.3
Salvetti, A.4
-
52
-
-
0031406824
-
Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension
-
Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10: 1326-34.
-
(1997)
Am J Hypertens
, vol.10
, pp. 1326-1334
-
-
Blacher, J.1
Amah, G.2
Girerd, X.3
-
53
-
-
0032169994
-
Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
-
Duprez DA, DeBuyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-6.
-
(1998)
Eur Heart J
, vol.19
, pp. 1371-1376
-
-
Duprez, D.A.1
DeBuyzere, M.L.2
Rietzschel, E.R.3
-
54
-
-
0031930133
-
Neurohumoral activity and left ventricular geometry in patients with essential hypertension
-
Muscholl MW, Schunkert H, Muders F, et al. Neurohumoral activity and left ventricular geometry in patients with essential hypertension. Am Heart J 1998; 135: 58-66.
-
(1998)
Am Heart J
, vol.135
, pp. 58-66
-
-
Muscholl, M.W.1
Schunkert, H.2
Muders, F.3
-
55
-
-
0027457073
-
Influence of arterial pressure and aldosterone in left ventricular hypertrophy in moderate essential hypertension
-
Duprez DA, Bauwens FR, Buyzere ML, et al. Influence of arterial pressure and aldosterone in left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17A-20A.
-
(1993)
Am J Cardiol
, vol.71
-
-
Duprez, D.A.1
Bauwens, F.R.2
Buyzere, M.L.3
-
56
-
-
0035108054
-
Arterial pressure, left ventricular mass and aldosterone in essential hypertension
-
El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass and aldosterone in essential hypertension. Hypertension 2001; 37: 845-50.
-
(2001)
Hypertension
, vol.37
, pp. 845-850
-
-
El-Gharbawy, A.H.1
Nadig, V.S.2
Kotchen, J.M.3
-
57
-
-
0031886048
-
Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension
-
Fagard RH, Lijnen PJ, Petrov VV. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens 1998; 12: 195-202.
-
(1998)
J Hum Hypertens
, vol.12
, pp. 195-202
-
-
Fagard, R.H.1
Lijnen, P.J.2
Petrov, V.V.3
-
58
-
-
0034651798
-
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
-
Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
-
(2000)
Circulation
, vol.101
, pp. 594-597
-
-
Farquharson, C.A.1
Struthers, A.D.2
-
59
-
-
0033533456
-
Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
-
The RESOLVD Pilot Study Investigators
-
McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
-
(1999)
Circulation
, vol.100
, pp. 1056-1064
-
-
McKelvie, R.S.1
Yusuf, S.2
Pericak, D.3
-
60
-
-
0141617520
-
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy
-
Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-8.
-
(2003)
Am J Hypertens
, vol.16
, pp. 781-788
-
-
Sato, A.1
Saruta, T.2
-
61
-
-
0019946282
-
Increase in plasma aldosterone during prolonged captopril treatment
-
Lijnen PM, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982; 49: 1561-3.
-
(1982)
Am J Cardiol
, vol.49
, pp. 1561-1563
-
-
Lijnen, P.M.1
Staessen, J.2
Fagard, R.3
Amery, A.4
-
62
-
-
0034745049
-
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy
-
Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
-
(2001)
J Int Med Res
, vol.29
, pp. 13-21
-
-
Sato, A.1
Saruta, T.2
-
63
-
-
0036314951
-
Aldosterone break-through during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats
-
Naruse M, Tanabe A, Sato A, et al. Aldosterone break-through during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
-
(2002)
Hypertension
, vol.40
, pp. 28-33
-
-
Naruse, M.1
Tanabe, A.2
Sato, A.3
-
64
-
-
0034110317
-
Aldosterone antagonists in hypertension and heart failure
-
Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol 2000; 61: 52-60.
-
(2000)
Ann Endocrinol
, vol.61
, pp. 52-60
-
-
Mantero, F.1
Lucarelli, G.2
-
65
-
-
0023117413
-
Three new epoxyspironolactone derivatives: Characterization in vivo and in vitro
-
de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxyspironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-6.
-
(1987)
J Pharmacol Exp Ther
, vol.240
, pp. 650-656
-
-
Gasparo, M.1
Joss, U.2
Ramjoue, H.P.3
-
66
-
-
0035997359
-
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
-
Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-16.
-
(2002)
Am J Hypertens
, vol.15
, pp. 709-716
-
-
Weinberger, M.H.1
Roniker, B.2
Krause, S.L.3
Weiss, R.J.4
-
67
-
-
0038179527
-
Eplerenone: Cardiovascular protection
-
Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003; 107: 2512-8.
-
(2003)
Circulation
, vol.107
, pp. 2512-2518
-
-
Brown, N.J.1
-
68
-
-
0023620145
-
Efficacy and tolerance of spironolactone in essential hypertension
-
Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.
-
(1987)
Am J Cardiol
, vol.60
, pp. 820-825
-
-
Jeunemaitre, X.1
Chatellier, G.2
Kreft-Jais, C.3
-
69
-
-
0001847493
-
Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria
-
Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. (abstr) Am J Hypertens 2002; 15: 24A.
-
(2002)
Am J Hypertens
, vol.15
-
-
Epstein, M.1
Buckalew, V.2
Martinez, F.3
-
70
-
-
0037799888
-
Primary aldosteronism - Changing concepts in diagnosis and treatment
-
Young WF Jr. Primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-13.
-
(2003)
Endocrinology
, vol.144
, pp. 2208-2213
-
-
Young Jr., W.F.1
-
71
-
-
0037414091
-
Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients
-
Flack J, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003; 41: 1148-55.
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 1148-1155
-
-
Flack, J.1
Oparil, S.2
Pratt, J.H.3
-
72
-
-
0038673178
-
Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
-
White WB, Duprez D, St Hillaire R, et al. Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-6.
-
(2003)
Hypertension
, vol.41
, pp. 1021-1026
-
-
White, W.B.1
Duprez, D.2
St. Hillaire, R.3
-
73
-
-
21044451889
-
Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension
-
Burgess E, Niegowksa J, Tan KW, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension. (abstr) Am J Hypertens 2002; 15: OR-51.
-
(2002)
Am J Hypertens
, vol.15
-
-
Burgess, E.1
Niegowksa, J.2
Tan, K.W.3
-
74
-
-
0036330671
-
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients
-
Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-23.
-
(2002)
Hypertension
, vol.40
, pp. 117-123
-
-
Krum, H.1
Nolly, H.2
Workman, D.3
-
75
-
-
0028911936
-
Increased serum concentrations of procollagen peptides in essential hypertension: Relation to cardiac alterations
-
Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-6.
-
(1995)
Circulation
, vol.91
, pp. 1450-1456
-
-
Diez, J.1
Laviades, C.2
Mayor, G.3
Gil, M.J.4
Monreal, I.5
-
76
-
-
0032508355
-
Abnormalities of the extracellular degradation of collagen type I in essential hypertension
-
Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-40.
-
(1998)
Circulation
, vol.98
, pp. 535-540
-
-
Laviades, C.1
Varo, N.2
Fernandez, J.3
-
77
-
-
0033916114
-
Fibrosis and hypertensive heart disease
-
Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-72.
-
(2000)
Curr Opin Cardiol
, vol.15
, pp. 264-272
-
-
Weber, K.T.1
-
78
-
-
0025826964
-
Impaired diastolic function and coronary reserve in genetic hypertension: Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries
-
Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-15.
-
(1991)
Circ Res
, vol.69
, pp. 107-115
-
-
Brilla, C.G.1
Janicki, J.S.2
Weber, K.T.3
-
79
-
-
0021267705
-
Left ventricular diastolic function in hypertension: Relation to left ventricular mass and systolic function
-
Fouad FM, Slominski M, Tarazi RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984; 3: 1500-6.
-
(1984)
J Am Coll Cardiol
, vol.3
, pp. 1500-1506
-
-
Fouad, F.M.1
Slominski, M.2
Tarazi, R.C.3
-
80
-
-
0026092229
-
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
-
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JM. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52.
-
(1991)
Ann Intern Med
, vol.114
, pp. 345-352
-
-
Koren, M.J.1
Devereux, R.B.2
Casale, P.N.3
Savage, D.D.4
Laragh, J.M.5
-
81
-
-
0029962323
-
Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
-
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
-
(1996)
JAMA
, vol.275
, pp. 1507-1513
-
-
Schmieder, R.E.1
Martus, P.2
Klingbeil, A.3
-
82
-
-
0038642326
-
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
-
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6.
-
(2003)
Am J Med
, vol.115
, pp. 41-46
-
-
Klingbeil, A.U.1
Schneider, M.2
Martus, P.3
Messerli, F.H.4
Schmieder, R.E.5
-
83
-
-
0026681461
-
Left ventricular function after reversal of myocardial hypertrophy in systemic hypertension and response to acute increase of after-load by cold pressor test
-
Grandi AM, Venco A, Bertolini A, et al. Left ventricular function after reversal of myocardial hypertrophy in systemic hypertension and response to acute increase of after-load by cold pressor test. Am J Cardiol 1992; 69: 1439-41.
-
(1992)
Am J Cardiol
, vol.69
, pp. 1439-1441
-
-
Grandi, A.M.1
Venco, A.2
Bertolini, A.3
-
84
-
-
0028862341
-
Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: Perindopril versus isradipine
-
Grandi AM, Bignotti M, Gaudio G, Zanzi P, Guasti L, Venco A. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995; 26: 737-41.
-
(1995)
J Cardiovasc Pharmacol
, vol.26
, pp. 737-741
-
-
Grandi, A.M.1
Bignotti, M.2
Gaudio, G.3
Zanzi, P.4
Guasti, L.5
Venco, A.6
-
85
-
-
0034687149
-
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
-
Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93.
-
(2000)
Circulation
, vol.102
, pp. 1388-1393
-
-
Brilla, C.G.1
Funck, R.C.2
Rupp, H.3
-
86
-
-
0037160969
-
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
-
(2002)
Lancet
, vol.359
, pp. 1004-1010
-
-
Lindholm, L.H.1
Ibsen, H.2
Dahlof, B.3
-
87
-
-
0032951417
-
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension
-
Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22.
-
(1999)
Hypertens Res
, vol.22
, pp. 17-22
-
-
Sato, A.1
Suzuki, Y.2
Saruta, T.3
-
88
-
-
0035027569
-
High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients
-
Sato A, Takane H, Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 2001; 24: 99-104.
-
(2001)
Hypertens Res
, vol.24
, pp. 99-104
-
-
Sato, A.1
Takane, H.2
Saruta, T.3
-
89
-
-
0036867985
-
Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension
-
Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-42.
-
(2002)
Hypertens Res
, vol.25
, pp. 837-842
-
-
Sato, A.1
Hayashi, M.2
Saruta, T.3
-
90
-
-
0036841840
-
Aldosterone antagonist improves diastolic function in essential hypertension
-
Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-52.
-
(2002)
Hypertension
, vol.40
, pp. 647-652
-
-
Grandi, A.M.1
Imperiale, D.2
Santillo, R.3
-
91
-
-
0017837088
-
The study of left ventricular function from digitized echocardiograms
-
Upton MT, Gibson DG. The study of left ventricular function from digitized echocardiograms. Prog Cardiovasc Dis 1978; 20: 359-84.
-
(1978)
Prog Cardiovasc Dis
, vol.20
, pp. 359-384
-
-
Upton, M.T.1
Gibson, D.G.2
-
92
-
-
0026071321
-
Diastolic disease in left ventricular hypertrophy: Comparison of M-mode and Doppler echocardiography for the assessment of rapid ventricular filling
-
Lee CH, Hogan JC, Gibson DG. Diastolic disease in left ventricular hypertrophy: comparison of M-mode and Doppler echocardiography for the assessment of rapid ventricular filling. Br Heart J 1991; 65: 194-200.
-
(1991)
Br Heart J
, vol.65
, pp. 194-200
-
-
Lee, C.H.1
Hogan, J.C.2
Gibson, D.G.3
-
93
-
-
0142085752
-
Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study
-
Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-8.
-
(2003)
Circulation
, vol.108
, pp. 1831-1838
-
-
Pitt, B.1
Reichek, N.2
Willenbrock, R.3
|